생균 치료제 및 마이크로바이옴 CDMO 서비스 시장 : 세계 예측(2026-2032년)

The Live Biotherapeutic Products & Microbiome CDMO Service Market is projected to grow by USD 4.98 billion at a CAGR of 12.33% by 2032.

Live Biotherapeutic Products and Microbiome CDMO Services: Executive Overview

Live biotherapeutic products (LBPs) are defined microbial preparations intended to prevent, treat, or manage disease, excluding conventional vaccines. Microbiome contract development and manufacturing organization (CDMO) services support activities such as strain selection, cell banking, process development, analytical testing, formulation, clinical manufacturing, and commercial-scale production. The field is advancing as researchers seek more precise ways to influence microbial communities and their interactions with human health. Development remains technically demanding because products may contain multiple strains, require controlled oxygen conditions, and depend on tightly managed viability, identity, purity, and potency attributes.

Transformative Shifts Reshaping LBP Development and Manufacturing

The landscape is shifting from empirical probiotic development toward mechanism-led product design, defined consortia, engineered strains, and patient-specific microbiome profiling. Regulators and developers are placing greater emphasis on product characterization, reproducible manufacturing, contamination control, and clinically relevant potency assays. Manufacturing models are also evolving toward integrated platforms that combine anaerobic processing, advanced sequencing, cryopreservation, specialized fill-finish, and validated cold-chain logistics. These changes increase the value of early technical risk assessment and of development partners able to connect microbiology, process engineering, analytics, quality systems, and clinical supply execution.

Artificial Intelligence Accelerates Discovery, Characterization, and Quality Control

Artificial intelligence can support the field by analyzing metagenomic, metabolomic, transcriptomic, clinical, and manufacturing datasets to identify microbial signatures and prioritize candidate strains or consortia. Machine-learning tools may also help predict growth behavior, media performance, stability, and process deviations, while computer vision and multivariate monitoring can strengthen environmental and in-process quality control. However, AI outputs require curated datasets, validated workflows, interpretable decision criteria, and human oversight. Data harmonization, patient privacy, model drift, and regulatory acceptance remain important constraints, particularly when algorithms influence product selection, release testing, or clinical decisions.

Regional Insights: Capabilities and Regulatory Conditions Across Six Geographies

North America benefits from established biopharmaceutical infrastructure, active translational research, and experience with complex clinical manufacturing, while regulatory engagement remains central to defining product classification and evidence requirements. Europe combines strong microbiome research with sophisticated quality and advanced-therapy ecosystems, although country-level processes and European Union requirements must be coordinated. Asia-Pacific offers expanding bioprocessing capacity, major research communities, and increasing clinical-development activity, with capability maturity varying by jurisdiction. Latin America is developing research, clinical, and manufacturing networks but may face limits in specialized anaerobic infrastructure and logistics. The Middle East is investing in biotechnology and healthcare modernization, while access to specialized production and regulatory expertise remains uneven. Africa presents important microbiome research opportunities and unmet clinical needs, alongside constraints involving infrastructure, funding, cold-chain continuity, and specialized quality systems.

Group Insights: How Major Multilateral and Economic Blocs Shape Adoption

ASEAN countries are strengthening biotechnology collaboration and regional healthcare capacity, but differences in regulatory maturity and manufacturing infrastructure affect cross-border development. BRICS economies provide substantial scientific, clinical, and biomanufacturing resources, while alignment of standards and technology access remains important. The European Union supports coordinated research and market access through shared frameworks, alongside demanding requirements for quality, safety, and data integrity. G7 members contribute advanced discovery, clinical, regulatory, and manufacturing capabilities, with policy coordination influencing technology transfer and supply resilience. GCC states are building life-science capacity through healthcare investment and economic diversification, creating opportunities for specialized partnerships. NATO members collectively include many advanced biomedical ecosystems, although defense-related priorities are distinct from commercial LBP development and should not be treated as a single regulatory market.

Country Insights: Differentiated Research, Regulatory, and Manufacturing Environments

The United States combines deep biomedical research, venture activity, clinical infrastructure, and specialized manufacturing, with regulatory classification and evidence strategy requiring early attention. Canada offers strong microbiome research and public-sector scientific capacity, while scaling specialized production can require coordinated partnerships. The United Kingdom has prominent life-science and clinical research assets, with post-EU regulatory coordination relevant to development planning. France, Germany, Italy, and Spain contribute advanced academic, hospital, pharmaceutical, and bioprocessing capabilities within the broader European Union framework, though national implementation and procurement conditions differ. Australia combines strong medical research with geographically dispersed supply chains. China and Japan have substantial research, healthcare, and manufacturing capabilities, but developers must address local regulatory, data, and quality requirements. South Korea is expanding biopharmaceutical and clinical-manufacturing expertise. India offers extensive pharmaceutical and clinical capabilities, while specialized microbiome process controls and consistency remain key execution considerations. Brazil and Mexico provide important Latin American research and clinical platforms, with infrastructure, regulatory coordination, and logistics shaping project feasibility. Russia retains scientific and industrial capabilities, although sanctions, trade restrictions, and international collaboration constraints may affect sourcing, development, and access to global clinical networks.

Action Priorities for Leaders Building Reliable LBP Platforms

Leaders should define the target product profile and mechanism of action before selecting strains, then establish a development plan linking analytical methods to clinical endpoints. Invest early in strain authentication, genomic characterization, cell banking, anaerobic process control, contamination prevention, and stability studies. Use risk-based supplier qualification for media, single-use components, specialized equipment, and cold-chain services, with contingency plans for critical inputs. Select CDMO partners based on demonstrated handling of live, oxygen-sensitive, multi-strain, or otherwise complex biological products rather than general capacity alone. Establish data standards and governance before introducing AI, and ensure every model is validated for its intended use. Regulatory consultations, technology-transfer planning, comparability protocols, and release-testing strategies should be integrated before pivotal clinical supply decisions.

Research Methodology for the Executive Summary

This summary applies a qualitative, evidence-led framework to the defined LBP and microbiome CDMO service domain. It synthesizes established scientific and manufacturing principles covering product characterization, strain and consortium development, anaerobic processing, analytical control, formulation, stability, regulatory strategy, clinical supply, and logistics. Regional, group, and country discussion is structured around observable differences in research capacity, biopharmaceutical infrastructure, regulatory coordination, healthcare systems, and supply-chain conditions. No market estimates, market shares, forecasts, or company-specific claims are used. Because capabilities and policies change over time, project decisions should be verified against current primary regulatory guidance, peer-reviewed research, clinical-trial records, and audited facility documentation.

Conclusion: Execution Discipline Will Determine LBP and Microbiome Success

LBPs and microbiome CDMO services are progressing toward more defined products, stronger mechanistic evidence, and higher expectations for reproducible manufacturing. The central challenge is not discovery alone; it is translating complex microbial biology into a stable, measurable, scalable, and clinically credible product. Organizations that integrate microbiology, analytics, process engineering, quality, regulatory strategy, digital governance, and supply resilience will be better positioned to manage technical and operational risk. Regional and country conditions should guide partnership and facility choices, while disciplined validation remains essential from early strain selection through clinical and commercial supply.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Service Type

• 7.1. Introduction
• 7.2. Analytical Services
  • 7.2.1. Bioanalytical Testing
  • 7.2.2. Microbiological Testing
• 7.3. Clinical Development
  • 7.3.1. Phase I Trials
  • 7.3.2. Phase II Trials
  • 7.3.3. Phase III Trials
• 7.4. Commercial Manufacturing
  • 7.4.1. Downstream Processing
  • 7.4.2. Fill Finish
  • 7.4.3. Upstream Processing

8. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Technology Platform

• 8.1. Introduction
• 8.2. Encapsulation
  • 8.2.1. Microencapsulation
  • 8.2.2. Nanoencapsulation
• 8.3. Fermentation
  • 8.3.1. Aerobic Fermentation
  • 8.3.2. Anaerobic Fermentation
• 8.4. Genetic Engineering
  • 8.4.1. CRISPR
  • 8.4.2. Plasmid Engineering
• 8.5. Lyophilization
  • 8.5.1. Bulk Lyophilization
  • 8.5.2. Vial Lyophilization

9. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Therapeutic Area

• 9.1. Introduction
• 9.2. Gastrointestinal Disorders
• 9.3. Infectious Diseases
  • 9.3.1. Bacterial Infections
  • 9.3.2. Viral Infections
• 9.4. Metabolic Disorders
• 9.5. Oncology

10. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Route Of Administration

• 10.1. Introduction
• 10.2. Injectable
  • 10.2.1. Intravenous
  • 10.2.2. Subcutaneous
• 10.3. Oral
  • 10.3.1. Capsule
  • 10.3.2. Tablet
• 10.4. Rectal
• 10.5. Topical

11. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Project Phase

• 11.1. Introduction
• 11.2. Commercial
• 11.3. Phase I
• 11.4. Phase II
• 11.5. Phase III
• 11.6. Preclinical

12. Live Biotherapeutic Products & Microbiome CDMO Service Market, by End User

• 12.1. Introduction
• 12.2. Contract Research Organizations
• 12.3. Pharmaceutical Companies
• 12.4. Research Institutes

13. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 4D Pharma plc
• 17.2. AOBiome, Inc.
• 17.3. Assembly Biosciences, Inc.
• 17.4. Azitra, Inc.
• 17.5. Bacthera, S.A.
• 17.6. Biocodex, S.A.
• 17.7. BiomeBank Pty Ltd
• 17.8. Biose Industrie S.A.
• 17.9. BJP Laboratories, Inc.
• 17.10. Cerbios-Pharma SA
• 17.11. Chr. Hansen Holding A/S
• 17.12. Eligo Bioscience, Inc.
• 17.13. EnteroBiotix Ltd
• 17.14. Enterome, S.A.
• 17.15. Exeliom Biosciences, S.A.
• 17.16. Finch Therapeutics Group, Inc.
• 17.17. Ginkgo Bioworks, Inc.
• 17.18. Infant Bacterial Therapeutics IBT AB
• 17.19. Inpac Probiotics, Inc.
• 17.20. List Biological Laboratories, Inc.
• 17.21. Lonza Group Ltd
• 17.22. MaaT Pharma, S.A.
• 17.23. Microbiotica Ltd
• 17.24. MRM Health NV
• 17.25. NIZO B.V.
• 17.26. Quay Pharmaceuticals Ltd
• 17.27. Rebiotix, Inc.
• 17.28. Seres Therapeutics, Inc.
• 17.29. Synlogic, Inc.
• 17.30. Vedanta Biosciences, Inc.
• 17.31. WACKER Chemie AG

18. Key Experts